Goldsmith Lab combines drug discovery and mechanistic analysis to understanding protein kinases. 

The De Brabander Lab focuses on the synthesis of complex molecular architectures, including both designed and naturally occurring substances with novel structural features and interesting biological function. 

The Mangelsdorf/Kliewer Lab studies two signal transduction pathways that offer new therapeutic potential for treating diseases such as diabetes, obesity, cancer, and parasitism.

Qin Lab focuses on the development of novel synthetic transformations and strategies that will allow access to bioactive, complex natural products and efficient synthesis of pharmaceuticals and their derivatives.

The Ready Lab is engaged in the discovery and synthesis of biologically active small molecules

The Tambar Group develops new strategies and concepts in synthetic chemistry to address challenging problems in chemistry and biology.

Our lab works with murine disease models and employs Biochemistry, Molecular and Cell Biology to investigate brain glycogen metabolism and related neurodegenerative diseases.

My lab has a long-time interest in understanding the mechanisms of transcription and gene regulation in mammalian cells using initially cell-free systems reconstituted with purified gene-specific transcription factors, general cofactors, and components of the general transcription machinery to recapitulate transcriptional events in vitro. 

We focus on the discovery of targeted therapies for major drivers of cancer using protein chemistry, enzymology, structural biology, informatics and cell biology. Some of our favorite targets are RAS and kinase proteins.

We are developing inhibitors of pyrimidine biosynthesis and polyamine biosynthesis to treat malaria and African sleeping sickness. We study polyamine and nucleotide metabolism in African trypanosomes to learn about novel metabolism and regulation.